FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit FIIs and DIIs Increase Stake: Small-cap Pharma Company Reports Over 11 Times Jump in Net Profit The company reported an impressive over 11 times growth in net profit for the second quarter of FY25, with Profit After Tax (PAT) reaching Rs 17.94 crore compared to Rs 1.61 crore in the same period last year. Manoj Reddy Sama / Thursday, November 14, 2024 2 779 Article rating: 4.0 Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25. Read more
Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high Mukul Agrawal gains Rs 1,10,29,80,000 & Vijay Kedia gains 35,84,68,500 from this multibagger pharma stock; Scrip hit 20 per cent upper circuit & 52-week high The shares of the company saw a spurt in volume by more than 2 times. Kiran Shroff / Tuesday, November 12, 2024 0 301 Article rating: 5.0 The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years. Read more
Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches! Indian Pharma Company Scores Major USFDA Approval for Game-Changing Capsule, Plans 5+ New Product Launches! With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence Pushkar Shinde / Monday, November 11, 2024 0 94 Article rating: 5.0 With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence Read more
This Multibagger Pharma Stock Secures Strategic Foothold in Europe — Is It Set for Massive Growth? This Multibagger Pharma Stock Secures Strategic Foothold in Europe — Is It Set for Massive Growth? Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams Pushkar Shinde / Wednesday, November 6, 2024 0 344 Article rating: 3.8 Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams Read more
Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why Vijay Kedia & Mukul Agrawal’s Portfolio Multibagger Pharma Stock Falls Over 14 Per Cent In Past 1 Hour; Here’s Why The company has a market cap of over Rs 17,000 crore with a PE of 55x, an ROE of 27 per cent and an ROCE of 33 per cent. Kiran Shroff / Wednesday, November 6, 2024 0 850 Article rating: 4.5 The stock gave multibagger returns of 250 per cent in 1 year, 720 per cent in 3 years and a whopping 2,700 per cent in 5 years. Read more